{"source":"regulations-gov","name":"Regulations.gov dockets","kind":"widget","via":"native","records":[{"id":"DOT-OST-2002-12555-0308","title":"American Airlines, Inc.","subtitle":"DOT · Other · 2026-12-13","value":"","href":"https://www.regulations.gov/document/DOT-OST-2002-12555-0308","props":{"document_id":"DOT-OST-2002-12555-0308","title":"American Airlines, Inc.","agency":"DOT","comment_count":null,"document_type":"Other","posted_date":"2026-12-13T05:00:00Z","url":"https://www.regulations.gov/document/DOT-OST-2002-12555-0308"}},{"id":"FERC-2026-4324-0001","title":"Combined Filings","subtitle":"FERC · Notice · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FERC-2026-4324-0001","props":{"document_id":"FERC-2026-4324-0001","title":"Combined Filings","agency":"FERC","comment_count":null,"document_type":"Notice","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FERC-2026-4324-0001"}},{"id":"SEC-2026-4522-0001","title":"Application: Cboe Clear U.S., LLC, Temporary Registration as a Clearing Agency","subtitle":"SEC · Notice · 2026-07-24","value":"","href":"https://www.regulations.gov/document/SEC-2026-4522-0001","props":{"document_id":"SEC-2026-4522-0001","title":"Application: Cboe Clear U.S., LLC, Temporary Registration as a Clearing Agency","agency":"SEC","comment_count":null,"document_type":"Notice","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/SEC-2026-4522-0001"}},{"id":"ED_FRDOC_0001-1151","title":"Final Waivers and Extensions of the Project Periods with Funding: Native American Career and Technical Education Program","subtitle":"ED · Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/ED_FRDOC_0001-1151","props":{"document_id":"ED_FRDOC_0001-1151","title":"Final Waivers and Extensions of the Project Periods with Funding: Native American Career and Technical Education Program","agency":"ED","comment_count":null,"document_type":"Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/ED_FRDOC_0001-1151"}},{"id":"FAA-2024-0074-0005","title":"U.S. DOT/FAA - Decision","subtitle":"FAA · Other · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FAA-2024-0074-0005","props":{"document_id":"FAA-2024-0074-0005","title":"U.S. DOT/FAA - Decision","agency":"FAA","comment_count":null,"document_type":"Other","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FAA-2024-0074-0005"}},{"id":"FDA-2026-N-7231-0129","title":"Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec","subtitle":"FDA · Notice · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FDA-2026-N-7231-0129","props":{"document_id":"FDA-2026-N-7231-0129","title":"Cellular, Tissue, and Gene Therapies Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments—Biologics License Application (BLA) 125827, From Replimune, Inc. for Vusolimogene Oderparepvec","agency":"FDA","comment_count":null,"document_type":"Notice","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FDA-2026-N-7231-0129"}},{"id":"USCG-2026-0354-0001","title":"Safety Zone; Laguna Madre, South Padre Island, TX","subtitle":"USCG · Proposed Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0354-0001","props":{"document_id":"USCG-2026-0354-0001","title":"Safety Zone; Laguna Madre, South Padre Island, TX","agency":"USCG","comment_count":null,"document_type":"Proposed Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0354-0001"}},{"id":"EPA-HQ-OPPT-2025-2169-0067","title":"P-22-0163 PMN Sanitized","subtitle":"EPA · Supporting & Related Material · 2026-07-24","value":"","href":"https://www.regulations.gov/document/EPA-HQ-OPPT-2025-2169-0067","props":{"document_id":"EPA-HQ-OPPT-2025-2169-0067","title":"P-22-0163 PMN Sanitized","agency":"EPA","comment_count":null,"document_type":"Supporting & Related Material","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/EPA-HQ-OPPT-2025-2169-0067"}},{"id":"FDA-2026-V-7064-0002","title":"Acknowledgment Letter from FDA DMB to Wil Pitonyak","subtitle":"FDA · Other · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FDA-2026-V-7064-0002","props":{"document_id":"FDA-2026-V-7064-0002","title":"Acknowledgment Letter from FDA DMB to Wil Pitonyak","agency":"FDA","comment_count":null,"document_type":"Other","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FDA-2026-V-7064-0002"}},{"id":"FAA-2026-8484-0002","title":"William J. Coulson - Amendment","subtitle":"FAA · Other · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FAA-2026-8484-0002","props":{"document_id":"FAA-2026-8484-0002","title":"William J. Coulson - Amendment","agency":"FAA","comment_count":null,"document_type":"Other","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FAA-2026-8484-0002"}},{"id":"FDA-2026-V-8030-0002","title":"Acknowledgment Letter from FDA DMB to Clevelander South Beach","subtitle":"FDA · Other · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FDA-2026-V-8030-0002","props":{"document_id":"FDA-2026-V-8030-0002","title":"Acknowledgment Letter from FDA DMB to Clevelander South Beach","agency":"FDA","comment_count":null,"document_type":"Other","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FDA-2026-V-8030-0002"}},{"id":"USCG-2026-0275-0001","title":"Special Local Regulation; Conch Republic Navy Parade and Battle, Key West, FL","subtitle":"USCG · Proposed Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0275-0001","props":{"document_id":"USCG-2026-0275-0001","title":"Special Local Regulation; Conch Republic Navy Parade and Battle, Key West, FL","agency":"USCG","comment_count":null,"document_type":"Proposed Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0275-0001"}},{"id":"USCG-2026-0269-0001","title":"Special Local Regulations; Charleston Race Week, Charleston, SC","subtitle":"USCG · Proposed Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0269-0001","props":{"document_id":"USCG-2026-0269-0001","title":"Special Local Regulations; Charleston Race Week, Charleston, SC","agency":"USCG","comment_count":null,"document_type":"Proposed Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0269-0001"}},{"id":"EPA-HQ-OPPT-2025-2169-0066","title":"Significant New Use Rules on Certain Chemical Substances: Multi-walled Carbon Nanotubes","subtitle":"EPA · Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/EPA-HQ-OPPT-2025-2169-0066","props":{"document_id":"EPA-HQ-OPPT-2025-2169-0066","title":"Significant New Use Rules on Certain Chemical Substances: Multi-walled Carbon Nanotubes","agency":"EPA","comment_count":null,"document_type":"Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/EPA-HQ-OPPT-2025-2169-0066"}},{"id":"USCG-2026-0285-0001","title":"Special Local Regulations; Marine Events within the USCG East District","subtitle":"USCG · Proposed Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0285-0001","props":{"document_id":"USCG-2026-0285-0001","title":"Special Local Regulations; Marine Events within the USCG East District","agency":"USCG","comment_count":null,"document_type":"Proposed Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0285-0001"}},{"id":"USCG-2026-0282-0002","title":"USCG-2026-0282_SUPPORTINGDOCUMENTS","subtitle":"USCG · Supporting & Related Material · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0282-0002","props":{"document_id":"USCG-2026-0282-0002","title":"USCG-2026-0282_SUPPORTINGDOCUMENTS","agency":"USCG","comment_count":null,"document_type":"Supporting & Related Material","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0282-0002"}},{"id":"USCG-2026-0332-0002","title":"USCG-2026-0332_Supportingdocuments","subtitle":"USCG · Supporting & Related Material · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0332-0002","props":{"document_id":"USCG-2026-0332-0002","title":"USCG-2026-0332_Supportingdocuments","agency":"USCG","comment_count":null,"document_type":"Supporting & Related Material","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0332-0002"}},{"id":"USCIS-2010-0008-1288","title":"G-1055","subtitle":"USCIS · Supporting & Related Material · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCIS-2010-0008-1288","props":{"document_id":"USCIS-2010-0008-1288","title":"G-1055","agency":"USCIS","comment_count":null,"document_type":"Supporting & Related Material","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCIS-2010-0008-1288"}},{"id":"FDA-2026-N-6733-0001","title":"Medical Devices; Immunology and Microbiology Devices; Classification of the Over-the-Counter Test To Detect SARS-CoV-2 From Clinical Specimens","subtitle":"FDA · Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FDA-2026-N-6733-0001","props":{"document_id":"FDA-2026-N-6733-0001","title":"Medical Devices; Immunology and Microbiology Devices; Classification of the Over-the-Counter Test To Detect SARS-CoV-2 From Clinical Specimens","agency":"FDA","comment_count":null,"document_type":"Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FDA-2026-N-6733-0001"}},{"id":"USCG-2026-0472-0001","title":"Safety Zone; Lower Mississippi River, Vicksburg, MS","subtitle":"USCG · Proposed Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0472-0001","props":{"document_id":"USCG-2026-0472-0001","title":"Safety Zone; Lower Mississippi River, Vicksburg, MS","agency":"USCG","comment_count":null,"document_type":"Proposed Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0472-0001"}},{"id":"FDA-2026-N-7627-0001","title":"Medical Devices; General Hospital and Personal Use Devices; Classification of the Diabetes Digital Behavioral Therapeutic Device","subtitle":"FDA · Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FDA-2026-N-7627-0001","props":{"document_id":"FDA-2026-N-7627-0001","title":"Medical Devices; General Hospital and Personal Use Devices; Classification of the Diabetes Digital Behavioral Therapeutic Device","agency":"FDA","comment_count":null,"document_type":"Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FDA-2026-N-7627-0001"}},{"id":"FAA-2026-8152-0002","title":"U.S. DOT/FAA - Acknowledgement Letter","subtitle":"FAA · Other · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FAA-2026-8152-0002","props":{"document_id":"FAA-2026-8152-0002","title":"U.S. DOT/FAA - Acknowledgement Letter","agency":"FAA","comment_count":null,"document_type":"Other","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FAA-2026-8152-0002"}},{"id":"FDA-2026-V-7460-0002","title":"Acknowledgment Letter from FDA DMB to Timothy Kesecker","subtitle":"FDA · Other · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FDA-2026-V-7460-0002","props":{"document_id":"FDA-2026-V-7460-0002","title":"Acknowledgment Letter from FDA DMB to Timothy Kesecker","agency":"FDA","comment_count":null,"document_type":"Other","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FDA-2026-V-7460-0002"}},{"id":"FDA-2026-P-8162-0002","title":"Acknowledgement Letter from FDA DMB to Melanie Morales","subtitle":"FDA · Other · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FDA-2026-P-8162-0002","props":{"document_id":"FDA-2026-P-8162-0002","title":"Acknowledgement Letter from FDA DMB to Melanie Morales","agency":"FDA","comment_count":null,"document_type":"Other","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FDA-2026-P-8162-0002"}},{"id":"USCG-2026-0426-0002","title":"USCG-2026-0426_SUPPORTINGDOCUMENTS","subtitle":"USCG · Supporting & Related Material · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0426-0002","props":{"document_id":"USCG-2026-0426-0002","title":"USCG-2026-0426_SUPPORTINGDOCUMENTS","agency":"USCG","comment_count":null,"document_type":"Supporting & Related Material","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0426-0002"}},{"id":"USCG-2026-0410-0001","title":"Safety Zone; Laguna Madre, South Padre Island, TX","subtitle":"USCG · Proposed Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0410-0001","props":{"document_id":"USCG-2026-0410-0001","title":"Safety Zone; Laguna Madre, South Padre Island, TX","agency":"USCG","comment_count":null,"document_type":"Proposed Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0410-0001"}},{"id":"USCG-2026-0426-0001","title":"Safety Zone; Lake Erie, Ashtabula, OH","subtitle":"USCG · Proposed Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0426-0001","props":{"document_id":"USCG-2026-0426-0001","title":"Safety Zone; Lake Erie, Ashtabula, OH","agency":"USCG","comment_count":null,"document_type":"Proposed Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0426-0001"}},{"id":"USCG-2026-0533-0001","title":"Safety Zone; Upper Mississippi River, Lake City, MN","subtitle":"USCG · Proposed Rule · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0533-0001","props":{"document_id":"USCG-2026-0533-0001","title":"Safety Zone; Upper Mississippi River, Lake City, MN","agency":"USCG","comment_count":null,"document_type":"Proposed Rule","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0533-0001"}},{"id":"USCG-2026-0799-0002","title":"USCG-2026-0799_Supportingdocuments","subtitle":"USCG · Supporting & Related Material · 2026-07-24","value":"","href":"https://www.regulations.gov/document/USCG-2026-0799-0002","props":{"document_id":"USCG-2026-0799-0002","title":"USCG-2026-0799_Supportingdocuments","agency":"USCG","comment_count":null,"document_type":"Supporting & Related Material","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/USCG-2026-0799-0002"}},{"id":"FDA-2026-H-7989-0001","title":"Complaint","subtitle":"FDA · Other · 2026-07-24","value":"","href":"https://www.regulations.gov/document/FDA-2026-H-7989-0001","props":{"document_id":"FDA-2026-H-7989-0001","title":"Complaint","agency":"FDA","comment_count":null,"document_type":"Other","posted_date":"2026-07-24T04:00:00Z","url":"https://www.regulations.gov/document/FDA-2026-H-7989-0001"}}],"count":30,"generated_at":"2026-07-25T12:28:27.065Z"}